Friedemann Zengerling

Author

Also Known As

Ademi Santiago-Walker, D. Nettersheim, F Zengerling, F. Zengerling, F., Zengerling, FRIEDEMANN ZENGERLING, Friedemann Zengerling, Hannah Stöckl, Michael Goetz, Wolfgang Thaiss

224

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

University Hospital Ulm Universität Ulm Heinrich Heine University Düsseldorf Heidelberg University Universitätsklinikum Erlangen

About

Friedemann Zengerling is an author at University Hospital Ulm specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	526
2	Cell Biology	5	5	123
3	Endocrinology	2	2	56
4	Health Sciences	1	1	58
5	Public Health	1	1	35

Friedemann Zengerling

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study Klaus‐Peter Dieckmann, Arlo Radtke, Lajos Géczi, Journal of Clinical Oncology	2019	330
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial Sumanta K. Pal, Laurence Albigès, Piotr Tomczak, The Lancet UrologyGenitourinary CancerMedicineImmune Checkpoint InhibitorRenal Cell Carcinoma	2023	173
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract Cora N. Sternberg, Yohann Loriot, Nicholas D. James, European Urology	2019	132
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Journal of Clinical Oncology	2024	95
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial Alexandros Papachristofilou, Jens Bedke, Stefanie Hayoz, The Lancet Oncology Surgical OncologySingle-dose CarboplatinRadiation TherapyStage Iib SeminomaMedicine	2022	58
Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer Thomas Schnoeller, Florian Jentzmik, L. Rinnab, World Journal of Urology UrologyGenitourinary CancerMedicinePathologyFree Testosterone	2012	41
Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort Stefanie Zschäbitz, Nadine Biernath, Thomas Hilser, European Urology Open Science	2023	41
Inhibition of Glycogen Synthase Kinase-3β Counteracts Ligand-Independent Activity of the Androgen Receptor in Castration Resistant Prostate Cancer Stefanie V. Schütz, Andres Jan Schrader, Friedemann Zengerling, PLoS ONE Molecular PharmacologyAndrogen ReceptorUrologySignal TransductionTranslational Biology	2011	37
German second-opinion network for testicular cancer: Sealing the leaky pipe between evidence and clinical practice Friedemann Zengerling, Michael Hartmann, Axel Heidenreich, Oncology Reports Surgical OncologyCancer ManagementGynecologyGerman Second-opinion NetworkCancer Registration	2014	35
Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer Bianca Nitzsche, C Gloesenkamp, M. Schrader, British Journal of Cancer Novel CompoundsMedicinePharmacologyAnti-tumour ActivityAnti-cancer Agent	2012	35

Page 1